07 February 2024
07 February 2024
Pending a successful acquisition, Novartis will obtain pelabresib for myelofibrosis and tulmimetostat for solid tumours or lymphomas.
The company’s diluted earnings per share rose to $4.50 in financial year 2023 (FY 2023) from $3.64 in FY 2022.
The application is backed by positive outcomes from a Phase III clinical trial.
The Rockville facility will focus on advancing cancer treatment trials and drug supply.
The company's revenue in Q4 2023 was $9.35bn, up 28% compared with $7.30bn in the same quarter of the previous year.
RT-111 could offer an alternative dosing regimen for patients with psoriasis and other conditions compared to injectable biologics.
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
The Belgian women’s health company is exploring multiple asset and licensing sells as cash reserves diminish.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
